The results demonstrate that the blockade of TGF-β1/SMAD signaling with the new generation TGF-β1 receptor (TGF-β1R) antagonist, GW788388, dramatically inhibited the cardiac fibrosis and dysfunction in Npr1 mutant animals. The gene discussed is NPR1; the disease is fibrosis.